Advertisement

Anebulo Pharmaceuticals, Inc. ANEB

Set alert

Price alert · ANEB

All alert types
0.26 USD -0.02 -5.45%

At close · Oct 29

0.38 +0.12 +46.88%

After hours · Oct 29, 4:00 PM ET

Bid
0.36 × 2,500
Ask
0.37 × 2,500
0.8699 Day range 0.8699
0.001 52-week range 2.64
YTD
-74.26%
1 year
-90.15%
Open
0.8699
Prev close
0.275
Mkt cap
10.60M
Vol
100
Avg vol
184
EPS
-0.19
P/E
0.00
Div yield
0.00%
More statistics
Low
0.8699
High
0.8699
Forward P/E
-2.49
Beta
-1.01
Short ratio
1.94
Inst. own
28.32%
Dividend
0.00
Ex-div date
Earnings
Feb 11, 2025
50-d avg
1.60
200-d avg
2.14
1y target
8.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 13, 2024Earnings: -0.08; estimate 0; surprise —%
  • Nov 19, 2024Rating: Benchmark · Speculative Buy → Speculative Buy
  • Feb 11, 2025Earnings: —; estimate 0; surprise —%
Signals (71)
NameDateAgo
MACD: Buy SignalOct 23, 20261 week ago
RSI: OversoldOct 16, 20262 weeks ago
SMA: BearishSep 18, 20261 month ago
MACD: Sell SignalSep 18, 20261 month ago
MACD: Buy SignalSep 15, 20261 month ago
MACD: Sell SignalSep 14, 20261 month ago
SMA: BullishSep 3, 20261 month ago
MACD: Buy SignalSep 3, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
SMA: BearishAug 21, 20262 months ago
SMA: BullishAug 17, 20262 months ago
MACD: Buy SignalJul 21, 20263 months ago
RSI: OversoldJul 15, 20263 months ago
MACD: Sell SignalJul 6, 20263 months ago
SMA: BearishJun 16, 20264 months ago
SMA: BullishJun 15, 20264 months ago
MACD: Buy SignalJun 12, 20264 months ago
MACD: Sell SignalJun 2, 20265 months ago
MACD: Buy SignalMay 4, 20266 months ago
SMA: BearishApr 6, 20266 months ago
MACD: Sell SignalApr 6, 20266 months ago
RSI: OverboughtMar 18, 20267 months ago
SMA: BullishMar 17, 20267 months ago
MACD: Buy SignalFeb 19, 20268 months ago
MACD: Sell SignalFeb 6, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
RSI: OversoldJan 27, 20269 months ago
RSI: OversoldJan 23, 20269 months ago
MACD: Buy SignalJan 12, 20269 months ago
RSI: OversoldJan 8, 20269 months ago
SMA: BearishDec 22, 202510 months ago
RSI: OversoldDec 22, 202510 months ago
MACD: Sell SignalDec 19, 202510 months ago
MACD: Buy SignalDec 17, 202510 months ago
MACD: Sell SignalDec 5, 202511 months ago
SMA: BearishNov 26, 202511 months ago
SMA: BullishNov 25, 202511 months ago
MACD: Buy SignalNov 25, 202511 months ago
SMA: BearishNov 7, 202511 months ago
MACD: Sell SignalNov 3, 202512 months ago
MACD: Buy SignalOct 15, 20251 year ago
SMA: BullishOct 14, 20251 year ago
MACD: Sell SignalOct 2, 20251 year ago
SMA: BearishSep 23, 20251 year ago
MACD: Buy SignalSep 17, 20251 year ago
SMA: BullishSep 12, 20251 year ago
SMA: BearishSep 8, 20251 year ago
MACD: Sell SignalAug 5, 20251 year ago
MACD: Buy SignalJul 23, 20251 year ago
RSI: OverboughtJul 23, 20251 year ago
MACD: Sell SignalJul 14, 20251 year ago
RSI: OverboughtJul 1, 20251 year ago
RSI: OverboughtJun 18, 20251 year ago
RSI: OverboughtJun 13, 20251 year ago
SMA: BullishJun 5, 20251 year ago
MACD: Buy SignalMay 19, 20251 year ago
MACD: Sell SignalMay 13, 20251 year ago
MACD: Buy SignalApr 24, 20251 year ago
SMA: BearishMar 27, 20251 year ago
MACD: Sell SignalMar 27, 20251 year ago
RSI: OverboughtMar 19, 20251 year ago
SMA: BullishMar 14, 20251 year ago
MACD: Buy SignalMar 11, 20251 year ago
RSI: OversoldMar 4, 20251 year ago
SMA: BearishFeb 20, 20251 year ago
SMA: BullishFeb 19, 20251 year ago
SMA: BearishFeb 10, 20251 year ago
MACD: Sell SignalJan 24, 20251 year ago
MACD: Buy SignalDec 24, 20241 year ago
RSI: OversoldDec 19, 20241 year ago
RSI: OversoldNov 25, 20241 year ago

Key statistics

Market cap
42.01M
Enterprise value
36.32M
Trailing P/E
0.00
Forward P/E
-2.49
PEG ratio
0.00
Price / sales
0.00
Price / book
11.02
EPS (TTM)
-0.30
Beta
-1.01
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-5.18M
Total cash
3.09M
Total debt
0
Return on equity
-113.80%
Shares outstanding
25.93M
Short % of float
0.28%
50-day average
1.60
200-day average
2.14

Analyst view

Consensus: none

Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 11, 2025

Expected Feb 11, 2025. Consensus EPS estimate -0.08.

Earnings history

Financials — quick view

All financials
ANEB Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 2025
ANEB Net income — quarterly -2.00M
2022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 2025
ANEB EPS — quarterly -0.05
2022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 2025

Earnings

ANEB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2025Dec 1, 20240.00———
Nov 13, 2024Sep 1, 20240.00-0.08——
Sep 25, 2024Jun 1, 20240.00———
Sep 25, 2024Jun 1, 20240.00-0.05——
May 15, 2024Mar 1, 2024-0.11———
May 15, 2024Mar 1, 2024-0.11-0.06+0.05+45.45%

Upgrades / downgrades

ANEB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2024BenchmarkreitSpeculative BuySpeculative Buy
Oct 1, 2024BenchmarkreitSpeculative BuySpeculative Buy
Oct 3, 2023BenchmarkreitSpeculative BuySpeculative Buy
Sep 25, 2023HC Wainwright & Co.reitBuyBuy
Sep 21, 2023Maxim Groupinit—Buy
Sep 18, 2023HC Wainwright & Co.init—Buy

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
anebulo.com

News

Your note

Sign in to keep a note on ANEB — it syncs with the Stock Master app.

Insider holders

ANEB insider holders
InsiderRelationLatest transactionDateShares held
ENGLISH ARON RDirector and Beneficial Owner of more than 10% of a Class of SecurityStock GiftDec 17, 20230

Institution ownership

ANEB institution ownership
Holder% heldSharesValueReported
22NW, LP20.69%5,366,2908.69MSep 29, 2024
LVW Advisors, LLC2.47%641,0391.04MSep 29, 2024
Nantahala Capital Management, LLC1.97%511,073827.94KSep 29, 2024
Morgan Stanley1.54%399,219646.73KSep 29, 2024
Ikarian Capital, LLC0.61%157,862255.74KSep 29, 2024
Vanguard Group Inc0.59%154,036249.54KSep 29, 2024

Fund ownership

ANEB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.47%121,000196.02KSep 29, 2024
Fidelity Extended Market Index Fund0.21%53,43186.56KOct 30, 2024
Vanguard Extended Market Index Fund0.13%33,03653.52KSep 29, 2024
Fidelity Total Market Index Fund0.06%14,72823.86KOct 30, 2024
Fidelity Series Total Market Index Fund0.05%11,84019.18KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%4,1086.65KOct 30, 2024
Advertisement